title: Regimen of ovarian stimulation affects oocyte and therefore embryo quality.
abstract: Without any doubt the regimen used to mature multiple capable oocytes for IVF impacts IVF outcomes. Studies have indicated that the inclusion of LH activity, adjuvant agents such as growth hormone (GH), and regimens providing for simultaneous action of both LH and FSH during final oocyte maturation may have beneficial effects on IVF outcomes. Because of the difficulty in improving IVF outcomes in poor responders, the studies on GH are of particular interest. As pointed out in this review, the apparent beneficial effects of GH on oocyte competence may also apply to older women or to normal responders with reduced embryo quality. A much more difficult question is whether and how much ovarian stimulation impacts on oocyte competence. Paradoxically it seems that there are not demonstrated differences between the stimulated and the natural unstimulated cycle, whereas studies in laboratory animals and IVF patients have shown deleterious effects of higher compared with lower doses of gonadotropins. Recent studies suggest that the use of high doses of gonadotropins as an independent factor correlates negatively with the probability of live birth, whereas a high ovarian response per se is associated with better cumulative pregnancy rates, owing to the availability of more euploid and good-quality embryos. Although adjunctive use of androgens has not been discussed here, it is briefly covered in the first review of this series.
authors.affiliation: Instituto Valenciano de Infertilidad, Valencia, Spain. Electronic address: Ernesto.Bosch@ivi.es.
authors.forename: Ernesto
authors.initials: E
authors.lastname: Bosch
authors.affiliation: Instituto Valenciano de Infertilidad, Valencia, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Labarta
authors.affiliation: 1st Department of Obstetrics and Gynecology, Papageorgiou General Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Efstratios
authors.initials: E
authors.lastname: Kolibianakis
authors.affiliation: Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California.
authors.forename: Mitchell
authors.initials: M
authors.lastname: Rosen
authors.affiliation: Reproductive Partners La Jolla, San Diego, California.
authors.forename: David
authors.initials: D
authors.lastname: Meldrum
mesh_terms: D000818:Animals; D001755:Blastocyst / Q000187:drug effects* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D010064:Embryo Implantation / Q000187:drug effects; D004624:Embryo Transfer; D005260:Female; D005298:Fertility / Q000187:drug effects*; D005300:Fertility Agents, Female / Q000009:adverse effects / Q000627:therapeutic use*; D005307:Fertilization in Vitro; D006801:Humans; D007246:Infertility / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D009865:Oocytes / Q000187:drug effects* / Q000473:pathology; D010053:Ovary / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D010060:Ovulation / Q000187:drug effects; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D005300:Fertility Agents, Female
keywords: Ovarian stimulation; gonadotropins; growth hormone; oocyte quality